Pharma News

AC-0676 by Accutar Biotechnology for Follicular Lymphoma: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AC-0676 overview

AC-0676 is under development for the treatment of autoimmune disorders, relapsed/refractory B-cell malignancies (hematological cancers), relapsed/refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), follicular lymphoma (FL), non-GCB diffuse large b-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), or Waldenström macroglobulinemia (WM). The drug candidate targets wild type and c481s mutated froms of tyrosine protein kinase BTK. It is administered through oral route.

Accutar Biotechnology overview

Accutar Biotechnology (Accutar Biotech) is a biotechnology company that employs artificial intelligence to revolutionize drug discovery. It is headquartered in Brooklyn, New York, the US.

For a complete picture of AC-0676’s drug-specific PTSR and LoA scores, buy the report here.




Source link
#AC0676 #Accutar #Biotechnology #Follicular #Lymphoma #Likelihood #Approval

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *